As the second textbook on “histiocytic disorders” is about to be published, the world of histiocytoses has never been more exciting and challenging at the same time. Exceptional advances in molecular and cellular biology have led to rapid changes in diagnostic and therapeutic modalities and have revolutionized the way we view most histiocytic disorders today. Once considered to be disorders of immune regulation, Langerhans cell histiocytosis (LCH) and Erdheim-Chester disease (ECD) are now considered as inflammatory myeloid neoplasms thanks to the discovery of BRAF-V600E and MAP2K mutations in two-thirds of these patients. One of the most important priorities of this textbook is to discuss the new genomic findings in all histiocytic neoplasms and related disorders and to shed more light on the new pathophysiological and genetic findings in hemophagocytic lymphohistiocytosis (HLH). The 2016 revised classification of histiocytic disorders will also be explained, and this will take into account all the most recent molecular and genomic findings merged with clinical categories.

This book will include four sections: the first one is dedicated to the pathology of all histiocytic disorders and is written by the top two world pathology experts on histiocytoses; section 2 is dedicated to LCH in children and adults, central nervous system (CNS) LCH, and first-line treatment of pediatric and adult LCH as well as treatment of refractory and relapsed LCH, with chemotherapy and BRAF inhibitors as well as new hematopoietic stem cell transplantation (HSCT) modalities, with an updated chapter on late effects after LCH. The third section is dedicated to HLH, in particular its diagnostic and clinical features, genetics and pathophysiology, with dedicated chapters on CNS-HLH, EBV-related HLH, malignancy-associated HLH, and macrophage-activation syndrome (MAS). These are followed by chapters on frontline treatment, treatment of refractory/relapsed HLH, HSCT and novel therapies, and finally adult HLH. Section 4 includes the uncommon histiocytic disorders with dedicated chapters on juvenile xanthogranuloma (JXG) and JXG-like disorders, ECD, Rosai-Dorfman disease (RDD), and malignant histiocytoses.

All chapters were written by distinguished experts in each field. We would like to take this opportunity to thank all of them for their efforts and time but also to thank several junior physicians who assisted these experts on specific chapters. We are also very grateful for the editorial assistance of Andy Kwan in New York and of Rahul Kumar Sharma in India, who have shown extraor-
dinary dedication and patience in managing the flow of many manuscripts, figures, and permissions.

We hope this book will serve as a comprehensive and updated tool for all pediatric and adult hematologists, oncologists, immunologists, pathologists, and trainees who will be looking after patients with histiocytic disorders.

Toronto, Canada  Oussama Abla, MD
Hamburg, Germany  Gritta Janka, MD, PhD
Histiocytic Disorders
Abla, O.; Janka, G. (Eds.)
2018, XII, 392 p. 96 illus., 74 illus. in color., Hardcover
ISBN: 978-3-319-59631-0